SCHEMBL7150454

SCHEMBL7150454

CN(Cc1ccccc1)C(=O)[C@H]1C[C@@H](S)CN1S(=O)(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MME P08473 2/20 0.48
ACE P12821 2/20 0.48
ECE1 P42892 2/20 0.48
MMP3 P08254 2/20 0.45
MMP1 P03956 1/20 0.45
MMP13 P45452 1/20 0.45
CA9 Q16790 3/20 0.44
MMP2 P08253 3/20 0.44
MMP9 P14780 3/20 0.44
CA12 O43570 2/20 0.44
POLB P06746 1/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CPT2 P23786 1/20 0.42
CPT1A P50416 1/20 0.42
MMP8 P22894 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7138312 1.00 ALDH1A1 (0.48) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7137745 0.89 ALDH1A1 (0.47) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7143331 0.89 MMP1 (0.58) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7141588 0.89 ALDH1A1 (0.47) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7135937 0.87 ECE1 (0.63) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7134758 0.87 ECE1 (0.63) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7135953 0.87 ECE1 (0.63) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7142447 0.86 MMP3 (0.51) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7144894 0.85 POLB (0.54) ALDH1A1KDM4EMMEACEECE1
SCHEMBL7141026 0.85 POLB (0.54) ALDH1A1KDM4EMMEACEECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ALDH1A1 767/4885KDM4E 1295/4885MME 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.